anonymous
Guest
anonymous
Guest
...bid a 4th time. The stock will fall deep.
Because the final two bids included almost no cash. The deals were financed with 62 percent Takeda stock where it would have been a merger where we remained majority stockholder with a 51 percent share.
That isn't too badBecause the final two bids included almost no cash. The deals were financed with 62 percent Takeda stock where it would have been a merger where we remained majority stockholder with a 51 percent share.
That isn't too bad
AbbVie offered $64B in 2014 before we went out and bought all that rare disease debt.Watch now as the stock crashes and Flem’s hopes of a big pay day are gone! The board got wayyyy too greedy! 63 billion? Who th fu*k else will buy us for anything more??
Flem will continue to ruin this company... remember this day people.
Abbvie is back in the hunt and their stock price took a hit today. Our reputation is terrible.
it's typical that a company making an offer drops in stock value.We are so toxic the mere mention that Allergan may have been interested sent their stock in a free fall.
Abbvie is back in the hunt and their stock price took a hit today. Our reputation is terrible.
https://finance.yahoo.com/news/shire-plc-statement-proposal-takeda-160101568.html
4th offer....it gives more cash and 48 to 49 % holdings in the new Takeda....
Well I was someone who didn’t believe there would be a 4th offer. All Shire has to do is keep rejecting them and they come back stronger. It’s a shame Phlem is going to make out like a bandit in this.
Well I was someone who didn’t believe there would be a 4th offer. All Shire has to do is keep rejecting them and they come back stronger. It’s a shame Phlem is going to make out like a bandit in this.